Back to Search
Start Over
Impact of revascularization guided by functional testing in ischaemic cardiomyopathy.
- Source :
-
European heart journal. Cardiovascular Imaging [Eur Heart J Cardiovasc Imaging] 2022 Sep 10; Vol. 23 (10), pp. 1304-1311. - Publication Year :
- 2022
-
Abstract
- Aims: The burden of ischaemia is a risk factor for adverse outcomes in ischaemic cardiomyopathy (ICM) but is not systematically tested when deciding on revascularization. Limited data exists in patients with ICM regarding the interaction between ischaemia and early coronary revascularization (ECR). This study sought to determine if the burden of ischaemia modifies the outcomes of ECR in ICM.<br />Methods and Results: Consecutive patients with ICM (left ventricular ejection fraction < 40%) with a stress-rest gated single-photon emission computed tomography (N = 747) were followed-up for ECR and major cardiovascular events (MACEs, cardiovascular death, myocardial infarction, or heart failure hospitalization). A 1:1 matched population was selected using a propensity score for ECR. The interaction between ischaemia and ECR was evaluated in the matched cohort. In the initial cohort, 131 patients underwent ECR. Of them, 109 were matched to non-ECR patients. After a median follow up of 4.1 years, 102 (46.8%) patients experienced a MACE. The effect of revascularization on MACE was dependent of the percent of ischaemia (P for the interaction at 10% ischaemia = 0.021), so that a trend towards a decreased risk of MACE was seen in patients with >10% of ischaemia [hazard ratio (HR) = 0.59 (0.30-1.18)], whereas a non-significant increase of MACE was observed in those with <10% ischaemia (HR = 1.67 [0.94-2.96]).<br />Conclusions: In a contemporary cohort of patients with ICM, the beneficial effects of ECR may be mediated by the percent of ischaemia. This study supports stress testing in ICM and an ischaemia-guided approach for ECR.<br />Competing Interests: Conflicts of interest: E.R.-A. has received non-conditioned grants from Biotronik, Micropport, Johnson&Johnson, Sanofi, and Sanofi Genzyme; none of them related to the current topic.<br /> (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Details
- Language :
- English
- ISSN :
- 2047-2412
- Volume :
- 23
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- European heart journal. Cardiovascular Imaging
- Publication Type :
- Academic Journal
- Accession number :
- 35781510
- Full Text :
- https://doi.org/10.1093/ehjci/jeac125